Achievement of a Negative MRD State After Hypomethylating Agent Therapy in Older Patients with AML to Reduce Risk of Relapse

Conference Correspondent - ASCO 2017 - Acute Myeloid Leukemia

The presence of minimal residual disease (MRD) is associated with poorer outcomes in patients with acute myeloid leukemia (AML) treated with traditional cytarabine- and anthracycline-based regimens. Researchers sought to understand whether the same dynamic exists for patients treated with hypomethylating agents.

In this study, 116 patients with AML treated with single-agent azacytidine, decitabine, or guadecitabine had MRD analysis performed on bone marrow specimens. The median age was 76 years. Sixty-nine (59%) patients achieved complete remission (CR) or CR with incomplete recovery of platelets or blood counts. The median number of cycles to achieve response was 2 (range, 1-6). Sixty-one patients (53%) had evaluable MRD data at the time of response, of whom 25 (41%) became MRD-negative at 3 months cumulative after CR.

MRD-negative status was associated with a reduced cumulative risk of relapse (P = 0.012) but not improved relapse-free survival (RFS) or overall survival (OS). The researchers concluded that this was due to a high frequency of nonrelapse deaths attributable to comorbidities and infections in the MRD-negative group. Likewise, patients who achieved MRD-negative status at CR and at any time up to 3 months postresponse were not associated with improved RFS or OS despite a significantly lower cumulative risk of relapse (P = 0.05).

In this group of older patients with AML treated with hypomethylating agents, achieving an MRD-negative state was associated with a reduced risk of relapse but not improved RFS or OS. Further research on patients experiencing a lower rate of nonrelapse mortality may be required to assess the true impact of MRD-negative status on survival.

Boddu P, et al. ASCO Abstract 7018.

Related Items
Suboptimal Adherence to Guideline-Recommended Molecular Testing in Patients with Newly Diagnosed AML: Data from the Connect MDS/AML Disease Registry
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia, Conference Correspondent
Effect of Cytarabine/Anthracycline/Crenolanib Induction on MRD in Newly Diagnosed FLT3 Mutant AML
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia
Differentiation Syndrome Associated with Enasidenib, a Selective Inhibitor of mIDH2
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia
Outcomes with Lower-Intensity Therapy in TP53-Mutated AML
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia
Enasidenib in Mutant-IDH2 Relapsed or Refractory AML: Results of a Phase 1 Dose-Escalation and Expansion Study
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia
Last modified: June 7, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME